1 – 10 of 94
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Morbiditet från urinvägar och tarm enligt registerdata efter ultrahypofraktionerad strålbehandling för lokaliserad prostatacancer vid 10 år i HYPO-RT-PC-studien
2024) Onkologidagarna 2024(
- Contribution to conference › Poster
-
Mark
Register data on long-term morbidity after prostate ultra-hypofractionation in the HYPO-RT-PC trial
(
- Contribution to conference › Abstract
-
Mark
Ultrahypofractionated Radiation Therapy for Prostate Cancer Including Seminal Vesicles in the Target Volume : A Treatment-planning Study Based on the HYPO-RT-PC Fractionation Schedule
(
- Contribution to journal › Article
- 2022
-
Mark
A prospective phase II study of prostate-specific antigen-guided salvage radiotherapy and 68Ga-PSMA-PET for biochemical relapse after radical prostatectomy - The PROPER 1 trial
(
- Contribution to journal › Article
-
Mark
Results from a prospective, randomised study on (accelerated) preoperative versus (conventional) postoperative radiotherapy in treatment of patients with resectable squamous cell carcinoma of the oral cavity – The ARTSCAN 2 study
(
- Contribution to journal › Article
-
Mark
Primary tumor volume and prognosis for patients with p16-positive and p16-negative oropharyngeal squamous cell carcinoma treated with radiation therapy
(
- Contribution to journal › Article
- 2021
-
Mark
Long-Term Risk of Hip Complications After Radiation Therapy for Prostate Cancer : A Dose-Response Study
(
- Contribution to journal › Article
-
Mark
Adaptive sequential plan-on-plan optimization during prostate-specific antigen response guided radiotherapy of recurrent prostate cancer
(
- Contribution to journal › Article
-
Mark
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC) : patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial
(
- Contribution to journal › Article
- 2020
-
Mark
PSA decay during salvage radiotherapy for prostate cancer as a predictor of disease outcome – 5 year follow-up of a prospective observational study
(
- Contribution to journal › Article